Mentice: From blood flow to cash flow - Redeye

Redeye initiates coverage of Mentice, a medtech company expanding its TAM many times over through vertical integration from endovascular simulation to IGIT performance solutions. We judge today’s share price represents an attractive entry opportunity for long-term-oriented investors should Mentice achieve its sales growth targets and improve its profitability.

Länk till analysen i sin helhet: https://www.redeye.se/research/870939/mentice-from-blood-flow-to-cash-flow?utm_source=finwire&utm_medium=RSS